ML-12
CLINICAL IMPACT AND MANAGEMENT OF SKIN-RELATED DISORDERS DURING TREATMENT OF RELAPSED PCNSL BY TIRABRUTINIB

Noriyuki Sasaki1, Keiichi Kobayashi1, Kunikazu Saito1, Ryo Onoda1, Yoshi Seiya1, Saki Suzuki1, Yukie Yamagishi2, Hirofumi Nakatomi2, Yoshiaki Shiozawa1, Motoo Nagane1, Department of Neurosurgery, Kyoto University Faculty of Medicine, Tokyo, Japan; 2Division of Brain Disease Translational Research, Juntendo University Faculty of Medicine, Tokyo, Japan

BACKGROUND: Tirabrutinib is a second-generation Bruton's tyrosine kinase (BTK) inhibitor, approved by the Japanese Pharmaceutical and Medical Devices Agency (PMDA) for relapsed and refractory PCNSL in March 2020. Skin-related disorder (SRD) is the most prevalent adverse event in tirabrutinib, which accounted for 44% in a phase II trial. While the use of tirabrutinib is increasingly considered in clinical practice, the prevalence and clinical impact of tirabrutinib-related SRDs in real-world practice remains unclear.

METHODS: Relapsed PCNSL patients treated with tirabrutinib at the author’s institution were identified, and divided into those with SRDs (SRD group), and without SRDs (non-SRD group). Response rate and progression-free survival (PFS) were retrospectively analyzed and compared between the two groups. RESULTS: Eleven patients were identified (median age: 73 [range: 50–83], median KPS: 70 [range: 40–90]), which included six (54.5%) from the SRD group and five (45.5%) from the non-SRD group. Response rate was 100% in the SRD group and 60% in the non-SRD group. Median PFS was 2.1 months in the SRD group and 36.3 months in the non-SRD group, which yielded no significant difference (p=0.446). While antihistamine prophylaxis using fexofenadine was performed in seven patients, among them SRDs were observed in three (27.3%), SRDs lead to tirabrutinib interruption (in more than ten days or more) in two (18.2%), dose reduction in three (27.3%), and discontinuation in two (18.2%) patients. Four patients in whom tirabrutinib was interrupted or discontinued due to SRDs had shorter PFS, compared with the two patients from the SRD group in whom tirabrutinib was continued (median PFS: 2.3 and 29.6 months, respectively) (p=0.049). CONCLUSIONS: SRDs substantially lead to tirabrutinib interruption or discontinuation, which could result in early PD. Since fexofenadine prophylaxis seems ineffective for preventing SRDs, other antihistamines should be considered. Establishment of the optimal management of tirabrutinib-related SRDs is warranted.

Key words: Tirabrutinib | PCNSL | Skin rash

ML-13
PRIMARY CENTRAL NERVOUS SYSTEM MALIGNANT LYMPHOMA IN A PATIENT WITH RHEUMATOID ARTHRITIS RECEIVING TOCILIZUMAB

Masakazu Ohno1, Syunichiro Kuramitsu2, Shouhei Ito2, Masayuki Kimata2, Takumi Aki2, Noriyuki Sasaki1, Yasukazu Kajita2, Tatsuo Tachahashi2, 1Department of Neurosurgery, Aichi Cancer Center Hospital, Nagoya, Japan; 2Department of Neurosurgery, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

Background: Although the risk of developing malignant lymphoma is higher in patients with rheumatoid arthritis (RA) than in the general population, the occurrence of primary central nervous system lymphoma (PCNSL) in patients with RA is extremely rare. In recent years, there has been concern that biological disease-modifying antirheumatic drugs (DMARDs), which are widely administered to patients with RA, may increase the risk of developing cancer. We report the first case of PCNSL in a patient with RA who was treated with the biological DMARDs, tocilizumab. Case description: A 70-year-old man, who was diagnosed with RA in 2010 was treated with low-dose methotrexate from 2010 to 2015. He was started on tocilizumab in 2012. In 2018, he suffered from gait disturbance and was diagnosed with lumbar spinal stenosis. He underwent L2/3 posterior fusion surgery, but his paraplegia gradually deteriorated. On MRI, gadolinium-enhanced T1-weighted contrast-enhanced lesions in the basal ganglia and brain stem. A stereotactic brain biopsy was performed and DLBCL was diagnosed, and finally PCNSL was diagnosed because of no neoplastic lesions in other organs. He was treated with 3 courses of R-CHOP plus rituximab and has been in remission for 23 months. He has maintained an independent life with residual paraplegia, but his ADLs gradually worsened. He was restaged on tocilizumab with a diagnosis of worsening RA. Conclusion: Low-dose methotrexate and biological DMARDs including tocilizumab, have been concerned to increase the risk of cancer in patients with RA, but there is no solid evidence. Since it has been a short time since the use of biological DMARDs, further accumulation of cases and careful follow-up are necessary.

Key words: Primary central nervous system lymphoma | Methotrexate | Tocilizumab

ML-16
FIRST CLINICAL EXPERIENCE OF ADMINISTRATION OF TIRABRUTINIB FOR THE PATIENTS WITH NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Sho Onodera1, Jiro Akimoto1; 1Department of Neurosurgery, Kohsei Chuo General Hospital

Tirabrutinib (TIR), a Bruton’s tyrosine kinase inhibitor, has been approved in Japan for treating relapsed/refractory primary central nervous system lymphoma (PCNSL). The authors recently encountered three patients with newly diagnosed refractory PCNSL using TIR.

Three patients, 48, 78 and 88 years-old males, diagnosed with PCNSL by histologically verification were firstly treated with high dose Methotrexate based chemotherapy (HD-MTX) and/or radiotherapy, however these cases were refractory for these standard treatments, demonstrated early cerebrospinal fluid dissemination or accompanied with severe adverse event. The authors decided to administrate TIR to these patients with a full informed consent. TIR demonstrated dramatic reduction of the volume of tumor on MRI within one month after administration of TIR, and improved the patient’s performance status. However, one case demonstrated liver dysfunction and multiple brain abscess due to aspergillus infection, and one case demonstrated early progression of the tumor 49 days after starting TIR.

Administration of TIR for the patients with newly diagnosed refractory PCNSL demonstrated a rapid and dramatic clinical response, and presented with several clinical implications for this complicated condition.

Key words: Tirabrutinib | refractory primary central nervous system lymphoma | adverse event

ML-17
CLINICAL USEFULNESS OF TIRABRUTINIB IN RECURRENT PCNSL: SINGLE INSTITUTE EXPERIENCE

Jin Matsura1, Jun-Ichiro Kuroda2, Tatsuya Takezaki3, Naoki Shinjojima1, Akitake Mukasa1; 1Department of Neurosurgery, University of Kumamoto, Kumamoto, Japan

Background: Primary central nervous system lymphoma (PCNSL) is a lymphoma whose primary lesion is localized in the brain and spinal cord. Treatment is a combination of high-dose methotrexate-based chemotherapy and whole-brain irradiation, often leading to recurrence. Pathologically, non-GCB type diffuse large B-cell lymphoma (DLBCL) predominates. In DLBCL, constitutive activation of B cell receptor signal (BCR) is the tumor mechanism of tumor development and growth. Tirabrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK) located downstream of BCR. In a phase 1/II study, an overall response rate was 64%. Currently, Tirabrutinib is used to treat relapsed or refractory PCNSL. Purpose: Tirabrutinib is a drug that has just been approved, and there are few reports of its use in clinical practice. We report on our experience with Tirabrutinib with a review of the literature. Methods: We retrospectively examined the clinical course of 11 recurrent PCNSL patients treated with Tirabrutinib at our institution. Results: The average age of the subjects was 68.7 years, and 7 cases were male. Tirabrutinib 480 mg was administered in all cases. The response rate was 60% (6/10 cases). The median progression-free survival was 4.3 months. The adverse events were Grade 3 neutropenia in 1 patient and Grade 2 skin disorder in 4 patients. Treatment was discontinued in 5 of the 11 patients due to progression of the disease. Conclusion: Based on our clinical experience, we have decided to reduce Tirabrutinib to 320 mg in 1 patient and discontinued in 1 patient. Treatment was discontinued at the request of the patient in 1 case, and four patients are still receiving treatment.